News & Updates
Filter by Specialty:
Show Multimedia Only

Alectinib trumps crizotinib for ALK+ NSCLC
13 Jan 2025
byAudrey Abella
In the 7-year update of the phase III ALESIA trial, alectinib outdoes crizotinib for Asian patients with treatment-naïve, advanced or metastatic ALK+ non-small-cell lung cancer (NSCLC).